SCHEMBL5535607

SCHEMBL5535607

[CH2]c1nc2c(Cl)cccc2o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.36
CYP2A6 P11509 2/20 0.36
PSMB8 P28062 4/20 0.35
LMNA P02545 2/20 0.35
PDE10A Q9Y233 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
NR4A2 P43354 2/20 0.33
HPGD P15428 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PSMB5 P28074 1/20 0.33
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954797 0.79 PSMB8 (0.37) CYP1A2CYP2A6PSMB8LMNAPDE10A
SCHEMBL31147003 0.76 PSMB8 (0.35) PSMB8LMNAPDE10ANPC1RAB9A
SCHEMBL5546209 0.76 DAGLA (0.40) LMNANPC1RAB9AALDH1A1MAPT
SCHEMBL5537227 0.76 ELANE (0.41) ALDH1A1KDM4E
SCHEMBL5485869 0.76 PSMB8 (0.35) CYP1A2CYP2A6PSMB8LMNAPDE10A
SCHEMBL10984833 0.76 LMNA (0.43) CYP1A2PSMB8LMNAPDE10ANPC1
SCHEMBL9563347 0.76 PSMB8 (0.35) PSMB8LMNAPDE10ANPC1RAB9A
SCHEMBL5077318 0.76 ELANE (0.44) PSMB8LMNAPDE10ANPC1RAB9A
SCHEMBL9846141 0.73 MAPT (0.38) PSMB8LMNAPDE10ANPC1RAB9A
SCHEMBL10829062 0.73 ELANE (0.37) MAPTMEN1GAAKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP1A2 659/4885CYP2A6 1119/4885PSMB8 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.